A Massachusetts federal jury has found in favor of Pfizer Inc., rejecting a plaintiff’s claims that he was not adequately warned of all of the risks of developing pulmonary arterial hypertension from using Pondimin, the Fen-Phen diet drug, according to the National Law Journal.

The jury last month found that Michael Tersigni had not shown by a preponderance of evidence that Wyeth-LLC, now a wholly-owned subsidiary of Pfizer, failed to adequately warn his doctor of the medical risks of using the drug. Pfizer had argued that Tersigni’s primary pulmonary hypertension (PPH), a medical condition characterized by elevated blood pressure in the blood vessels of his lungs, was most likely caused from his left-sided heart disease, according to the NLJ article. Pfizer also said that the Pondimin label warned Tersigni’s doctor of an association between the drug and PPH.